# Focusing on Innovation and Patients: Insights from Astellas Pharma CEO Naoki Okamura The Tokyo-based biopharmaceutical company is innovating at the intersection of biology, modality, and disease. - **Source:** [McKinsey Insights](https://www.mckinsey.com/insights) - **Published:** 2026-08-13 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/b7247ed7-9350-441a-a8f4-ab98dc118a7b ## Astellas Pharma's Innovation Strategy Tokyo-based biopharmaceutical company Astellas Pharma, under CEO Naoki Okamura's leadership, develops innovative solutions at the intersection of biology, treatment modalities, and disease mechanisms. The company adopts a multidisciplinary strategy that goes beyond traditional drug development approaches. Having increased R&D investments by 40% over the past 5 years, the company initiated 12 new clinical trials in rare diseases and oncology. This approach promises hope for patients with limited treatment options. ## Patient-Centric Drug Development Astellas Pharma's core focus is developing treatments centered around patient needs. The company implements a model that directly incorporates patient experiences into product development processes. Through the 'Patient Voices' program launched in 2023, feedback was collected from over 1,500 patients and caregivers. This data guides the development of new formulations that improve treatment adherence and reduce side effects. This approach, particularly aimed at improving quality of life in chronic diseases, sets an industry example. ## Modality Platforms and Technology Integration The company embraces a platform approach that integrates different treatment modalities like cell therapies, gene therapies, and small molecule drugs. The 'Modality Convergence' unit established in 2022 accelerates this integration. AI-powered drug discovery platforms have reduced development timelines by 30%. Collaborations with MIT and Tokyo University are advancing next-generation biomarker technologies. This multifaceted approach promises significant breakthroughs in personalized medicine. ## Global R&D Network and Local Collaborations Astellas Pharma conducts global R&D activities through more than 40 centers across 15 countries. In addition to research facilities in Japan, the US, and Europe, the company conducts clinical trials in emerging markets. Immuno-oncology studies jointly conducted with 3 university hospitals in Turkey focus on regional health needs. As part of its 2025 vision, 10 new manufacturing facilities are planned to increase access to biosimilars. This global yet localized strategy aims to democratize treatment access. ## Steps Toward a Sustainable Pharma Industry The company has committed to becoming carbon neutral by 2040 in line with environmental sustainability goals. New technologies have been developed that reduce water usage in drug manufacturing by 45%. Packaging waste has been reduced by 60% following circular economy principles. Over 500 suppliers have received training through the sustainable supply chain program. These efforts both reduce environmental footprint and provide long-term cost advantages. ## Digital Health Solutions and Data Management Astellas is investing in digital therapeutics and remote patient monitoring systems. The acquisition of a digital health startup in 2021 enabled development of smart medication platforms. AI algorithms created for real-world data (RWD) analyses evaluate treatment effectiveness in real time. Digital therapeutics for 5 different chronic diseases are currently in clinical trials. These initiatives accelerate the integration of traditional pharma with digital health ecosystems. ## Next-Generation Talent Development The company cultivates skilled workforce for the future of biopharmaceuticals. The 'Astellas University Program' provides scholarships and internships to over 1,000 students across 20 countries. 35% of employees regularly participate in cross-functional rotation programs. A special mentorship program supporting female leaders has increased women's representation on the board to 40%. These human capital investments strengthen long-term innovation capacity. ## Role in Transforming Healthcare Systems Astellas Pharma's strategy extends beyond drug development. The company works to make healthcare systems more accessible, affordable, and patient-centered. Access programs provide free or low-cost treatment to 10 million patients in developing countries. Collaborations with WHO improve access to essential medicines. This comprehensive approach positions the company not just as a drug manufacturer, but as a global health solutions partner. ## Sources covering this story - https://www.mckinsey.com/industries/life-sciences/our-insights/putting-innovation-and-patients-in-focus-a-conversation-with-astellas-pharma-ceo-naoki-okamura — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._